77215-55-5

Usage

Uses

Used in Pharmaceutical Research and Development:
(S)-3-AMINO-2-CBZ-AMINO-PROPIONIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of peptidomimetics and larger, more complex molecules. Its unique structure allows for the creation of new compounds with potential therapeutic applications, contributing to the advancement of drug discovery and development.
Used in Medicinal Chemistry:
(S)-3-AMINO-2-CBZ-AMINO-PROPIONIC ACID TERT-BUTYL ESTER is used as a key component in the design and synthesis of novel drug candidates. Its versatility in forming various molecular structures makes it an essential tool in the field of medicinal chemistry, aiding researchers in their quest to develop new and effective treatments for various diseases and conditions.

InChI:InChI=1/C15H22N2O4/c1-15(2,3)21-13(18)12(9-16)17-14(19)20-10-11-7-5-4-6-8-11/h4-8,12H,9-10,16H2,1-3H3,(H,17,19)/t12-/m0/s1

Upstream product

• 35761-26-3 (S)-3-amino-2-(((benzyloxy)carbonyl)amino)propanoic acid 
• 115-11-7 isobutene 
• 540-88-5 acetic acid tert-butyl ester 
• 7732-18-5 water 
• 1482-97-9 (S)-2,3-diaminopropanoic acid hydrochloride 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 178982-83-7 4-{2-[6-((S)-2-Benzyloxycarbonylamino-2-tert-butoxycarbonyl-ethylcarbamoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 197358-37-5 (S)-2-Benzyloxycarbonylamino-3-[2-((S)-4-methoxycarbonylmethyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino]-propionic acid tert-butyl ester 
• 197358-28-4 (S)-2-Benzyloxycarbonylamino-3-(2-{(S)-2,5-dioxo-4-[3-(pyrimidin-2-ylamino)-propyl]-imidazolidin-1-yl}-acetylamino)-propionic acid tert-butyl ester 
• 197358-13-7 2-benzyloxycarbonylamino-3-(2-{4-[3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl]-2,5-dioxo-imidazolidin-1-yl}-acetylamino)-propionic acid tert-butyl ester 
• 197358-32-0 3-(2-{4-[3-(1H-benzoimidazol-2-ylamino)-propyl]-2,5-dioxo-imidazolidin-1-yl}-acetylamino)-2-benzyloxycarbonylamino-propionic acid tert-butyl ester 
• 192944-78-8 tert-butyl 3-[1-[3-(N-pyridin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2(S)-(benzyloxycarbonylamino)propionate 
• 1026545-29-8 2-benzyloxycarbonylamino-3-({1-[3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl]-1H-indazole-4-carbonyl}-amino)-propionic acid tert-butyl ester 
• 792887-90-2 2-benzyloxycarbonylamino-3-({1-[3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl]-1H-indazole-5-carbonyl}-amino)-propionic acid tert-butyl ester 
• 1026292-64-7 2-benzyloxycarbonylamino-3-({1-[3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl]-1H-indazole-6-carbonyl}-amino)-propionic acid tert-butyl ester 
• 192944-67-5 2-benzyloxycarbonylamino-3-({1-[3-(tert-butoxycarbonyl-pyridin-2-yl-amino)-propyl]-1H-indazole-5-carbonyl}-amino)-propionic acid tert-butyl ester 
• 257293-60-0 2-benzyloxycarbonylamino-3-({1-[3-(1-trityl-1H-imidazol-2-ylamino)-propyl]-1H-indazole-5-carbonyl}-amino)-propionic acid tert-butyl ester 
• 736115-77-8 2-benzyloxycarbonylamino-3-{2-[4-(4-carbamimidoyl-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl]-acetylamino}-propionic acid tert-butyl ester 
• 250688-81-4 2-benzyloxycarbonylamino-3-{[5-(2-methoxycarbonyl-ethyl)-thiophene-2-carbonyl]-amino}-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same

A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.

αvβ3 antagonists based on a central benzoic acid scaffold

A series of novel, highly potent αvβ3 antagonists based on a benzoic acid scaffold and containing an acylguanidine as an Arg-mimetic and sulfonamide side chains is described. The compounds are selective against the fibrinogen recepto

5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists

Compounds of the formula I in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and h have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I and of pharmaceutical preparations which contain such compounds for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.

2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them

The present invention relates to imidazolidine compounds of the formula I, The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use in the therapy and prophylaxis of the disease states mentioned and pharmaceutical preparations which contain compounds of the formula I.

Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold

Antagonists of the platelet fibrinogen receptor (GP IIb/IIIa receptor) are expected to be a promising new class of antithrombotic agents. The binding of fibrinogen to the fibrinogen receptor depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif. Structural modifications of the RGDS lead have led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist 44 (S 1197). Compound 44 inhibited, in a dose dependent and reversible manner, human and dog platelet aggregation as well as 125I-fibrinogen binding to ADP-activated human gel filtered platelets and isolated GP IIb/IIIa with Ki values of 9 nM and 0.17 nM, respectively. A pharmacophore mapping procedure with QXP and a 3D-QSAR analysis applying the GRID/GOLPE methodology yielded a stable, rather predictive model and revealed structural features which are important for binding. Hydrophobic substitutions both at the hydantoin nucleus and at the C-terminus increase the affinity toward the fibrinogen receptor. The crystalline ethyl ester prodrug 48 (HMR 1794) is an orally active antithrombotic agent which is a promising drug candidate for the treatment of thrombotic diseases in humans.

Inhibitors or bone reabsorption and antagonists of vitronectin receptors

Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation a

Vitronectin receptor antagonists, their preparation and their use

The present invention relates to compounds of the formula IA-B-D-E-F-G(I)in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronecti

1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as alpha v beta 3 antagonists

This invention relates to 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles of Formula (I) which are useful as antagonists of alpha v beta 3 and related integrin receptors, to pharmaceutical compositions containing such compounds, alone or in combination with othe

Imino compounds, process for their preparation and their use as victronectin antagonists

There are described imino derivatives of formula (I) their preparation and their use as medicaments. The compounds according to the invention may be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

Non-peptide fibrinogen receptor antagonists. 2. The synthesis of [3H]L- 738,167

The synthesis of [2H]L-738,167, an orally active fibrinogen receptor antagonist, is described. A precursor containing the 2-bromotolyl moiety was synthesized, and a reductive debromination reaction using tritium gas and Pearlman's catalyst gave